A recent study investigated the potential effects of CBD on symptoms related to menstruation, finding that oral doses of CBD helped alleviate various symptoms such as stress, anxiety and irritability compared to participants’ initial conditions. However, depression levels remained unchanged throughout the study period.
The research study marks the first of its kind to explore the impact of cannabidiol specifically on menstrual-related symptoms (MRS) and general irritability. The findings indicated notable reductions in MRS, stress, irritability and anxiety after three months of CBD use compared to baseline measurements.
According to the authors, the results suggest that CBD could serve as an effective treatment for alleviating MRS. Given the limited options for managing MRS and its associated experiences, further exploration of CBD as a treatment option is deemed necessary.
Current remedies for MRS are limited, often involving lifestyle adjustments, behavioral therapies or over-the-counter (OTC) medications. Further, the authors noted that severe psychological symptoms may require pharmacotherapy or hormonal interventions, but these approaches are only effective for a portion of individuals and may entail side effects.
During the trial, participants were instructed to consume CBD softgels two times a day for five days at the onset of menstrual symptoms, for three months. Participants were divided into two groups, one receiving a 160-milligram dose of CBD twice daily and the other receiving 320 milligrams.
Exclusions from the study included individuals who had used marijuana in the past 30 days, those attempting to conceive, individuals with significant health conditions, minors and individuals outside the range of 18 to 55 years of age. One participant withdrew due to skin irritation after a single CBD dose.
Results showed consistent reductions in MRS, irritability, stress, symptom severity and anxiety across both dosage groups compared to baseline. These changes were observed as early as the first month and continued throughout the study period.
Published in the “Experimental and Clinical Psychopharmacology Journal,” the study disclosed support from marijuana companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) and Charlotte’s Web.
Limitations of the study included a relatively homogeneous sample, potentially oversampling individuals with moderate MRS severity. The absence of compensation for participants and reliance on self-reported CBD consumption were also noted, suggesting the need for more rigorous verification methods in future research.
Furthermore, the trial lacked a placebo control, leading the authors to acknowledge the possibility of observed symptom reductions being influenced by placebo effects. Despite these limitations, the study offers initial evidence supporting CBD as a management option for MRS, emphasizing the need for further investigation and optimization of CBD administration.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
